Printer Friendly

Trial Tests Stem Cell Transplantation Versus Best Available Therapy For MS.

SEATTLE, Wash., January 7, 2020 -- The Immune Tolerance Network (ITN) announced it has opened the BEAT-MS clinical trial for enrollment.

BEAT-MS or "Best Available Therapy vs. Autologous Hematopoietic Stem Cell Transplant (AHSCT) for MS" will investigate high dose immunosuppression followed by AHSCT--a type of transplant using a patient's own immune stem cells--compared to the best medical treatment available for multiple sclerosis (MS) in participants with relapsing MS.

Relapsing forms of MS are characterized by periods of time during which symptoms worsen (relapse), followed by periods of time in which symptoms get better (remission).

Incomplete recovery from relapses often leads to worsening disability.

More than a dozen therapies have been approved by the FDA for the treatment of relapsing MS.

However, despite this availability of an increasing number of treatment options, some patients with highly active disease do not achieve adequate disease control. In addition, side effects of therapy and the risk of relapse if therapy is stopped continue to be significant problems.

Previous studies have shown that AHSCT could be an effective and durable treatment for patients with relapsing MS whose disease is incompletely controlled by the currently available therapies.

BEAT-MS will be the first clinical trial in which the efficacy, safety, and cost-effectiveness of AHSCT will be directly compared to the best available treatments, chosen from among those recently approved for the treatment of MS that have not yet been tried by the study participant.

BEAT-MS is being conducted by the ITN, a program of Benaroya Research Institute at Virginia Mason, funded by the National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

The first open clinical site that will begin recruiting participants for BEAT-MS is Cleveland Clinic. BEAT-MS will be conducted at 19 clinical sites in the U.S. and in the U.K.

The Immune Tolerance Network (ITN) is a collaborative network for clinical research sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

Contact: http://www.immunetolerance.org

COPYRIGHT 2020 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Clinical TRIALS
Publication:Stem Cell Research News
Date:Jan 27, 2020
Words:342
Previous Article:Phase 2b DHELIVER Study Of Hepastem In Patients With Liver Failure: Results Expected In 2023.
Next Article:Mutations In Donors' Stem Cells May Cause Problems For Cancer Patients.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters